{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T07:25:37Z","timestamp":1777533937332,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1124\/jpet.111.187815","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T15:32:37Z","timestamp":1321457557000},"page":"433-444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["3-Substituted Pyrazole Analogs of the Cannabinoid Type 1 (CB1) Receptor Antagonist Rimonabant: Cannabinoid Agonist-Like Effects in Mice via Non-CB1, Non-CB2 Mechanism"],"prefix":"10.1016","volume":"340","author":[{"given":"Jenny L.","family":"Wiley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana E.","family":"Selley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pinglang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudresha","family":"Kottani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivas","family":"Gadthula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Mahadeven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.111.187815_bib1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0022-3565(24)37342-2","article-title":"Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain","volume":"284","author":"Adams","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0091-3057(02)00945-0","article-title":"SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study","volume":"74","author":"Bass","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.111.187815_bib3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0022-3565(24)38906-2","article-title":"Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition","volume":"295","author":"Breivogel","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.bjp.0707584","article-title":"CB2 receptors in the brain: role in central immune function","volume":"153","author":"Cabral","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.187815_bib5","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) on an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.111.187815_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","article-title":"Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials","volume":"370","author":"Christensen","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/jpet.111.187815_bib7","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0022-3565(25)12911-X","article-title":"In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of \u03949-tetrahydrocannabinol-induced responses and apparent agonist activity","volume":"277","author":"Compton","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0022-3565(25)38122-X","article-title":"Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities","volume":"265","author":"Compton","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bmcl.2009.11.047","article-title":"Exploring SAR features in diverse library of 4-cyanomethyl-pyrazole-3-carboxamides suitable for further elaborations as CB1 antagonists","volume":"20","author":"Cooper","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.111.187815_bib10","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"10.1124\/jpet.111.187815_bib11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s002130100734","article-title":"Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats","volume":"156","author":"Fattore","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.187815_bib12","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1021\/jm010498v","article-title":"Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB1 receptor antagonist N- (piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716)","volume":"45","author":"Francisco","year":"2002","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187815_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.neuropharm.2010.03.001","article-title":"Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists","volume":"58","author":"Gullapalli","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187815_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"10.1124\/jpet.111.187815_bib15","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1021\/jm060446b","article-title":"Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen\/lysine3.28(192) interaction","volume":"49","author":"Hurst","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187815_bib16","series-title":"Guide for the Care and Use of Laboratory Animals","year":"1996"},{"key":"10.1124\/jpet.111.187815_bib17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00213-004-1916-5","article-title":"Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist","volume":"177","author":"J\u00e4rbe","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.111.187815_bib18","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1021\/jm980363y","article-title":"Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists","volume":"42","author":"Lan","year":"1999","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.111.187815_bib19","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(97)01160-6","article-title":"SR141716A is an inverse agonist at the human cannabinoid CB1 receptor","volume":"334","author":"Landsman","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.187815_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/0091-3057(91)90349-7","article-title":"Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs","volume":"40","author":"Martin","year":"1991","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.111.187815_bib21","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/00001756-200107200-00018","article-title":"Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor","volume":"12","author":"Murillo-Rodr\u00edguez","year":"2001","journal-title":"Neuroreport"},{"key":"10.1124\/jpet.111.187815_bib22","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1196\/annals.1369.052","article-title":"Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain","volume":"1074","author":"Onaivi","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1124\/jpet.111.187815_bib23","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/mol.54.6.1064","article-title":"SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity","volume":"54","author":"Pan","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.111.187815_bib24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.111.187815_bib25","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0024-3205(95)00174-5","article-title":"Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist","volume":"56","author":"Rinaldi-Carmona","year":"1995","journal-title":"Life Sci"},{"key":"10.1124\/jpet.111.187815_bib26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1124\/jpet.111.187815_bib27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0024-3205(96)00347-5","article-title":"Cannabinoid receptor stimulation of guanosine-5\u2032-O-(3-[35S]thio)triphosphate binding in rat brain membranes","volume":"59","author":"Selley","year":"1996","journal-title":"Life Sci"},{"key":"10.1124\/jpet.111.187815_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0022-3565(25)20744-3","article-title":"Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands","volume":"278","author":"Showalter","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib29","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1016\/j.bmc.2005.06.005","article-title":"Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N- (piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide (SR141716) with unique binding selectivities and pharmacological activities","volume":"13","author":"Thomas","year":"2005","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.111.187815_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3565(24)37365-3","article-title":"Comparative receptor binding analyses of cannabinoid agonists and antagonists","volume":"285","author":"Thomas","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib31","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1124\/jpet.111.187815_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0028-3908(95)00027-4","article-title":"Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats","volume":"34","author":"Wiley","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.111.187815_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.bjp.0706157","article-title":"CB1 cannabinoid receptor-mediated modulation of food intake in mice","volume":"145","author":"Wiley","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.111.187815_bib34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-3565(24)37496-8","article-title":"Structure-activity relationships of indole- and pyrrole-derived cannabinoids","volume":"285","author":"Wiley","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib35","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0022-3565(24)38846-9","article-title":"Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation","volume":"296","author":"Wiley","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000065631","article-title":"Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity","volume":"66","author":"Wiley","year":"2002","journal-title":"Pharmacology"},{"key":"10.1124\/jpet.111.187815_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)12022-3","article-title":"Antagonism of the discriminative stimulus effects of \u03949-tetrahydrocannabinol in rats and rhesus monkeys","volume":"275","author":"Wiley","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.111.187815_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0009-3084(02)00146-9","article-title":"Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes","volume":"121","author":"Wiley","year":"2002","journal-title":"Chem Phys Lipids"},{"key":"10.1124\/jpet.111.187815_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0014-2999(03)01856-9","article-title":"Cannabinoid pharmacological properties common to other centrally acting drugs","volume":"471","author":"Wiley","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.111.187815_bib40","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1073\/pnas.96.10.5780","article-title":"Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice","volume":"96","author":"Zimmer","year":"1999","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524467335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524467335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.111.187815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:42:02Z","timestamp":1740019322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524467335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0022356524467335"],"URL":"https:\/\/doi.org\/10.1124\/jpet.111.187815","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3-Substituted Pyrazole Analogs of the Cannabinoid Type 1 (CB1) Receptor Antagonist Rimonabant: Cannabinoid Agonist-Like Effects in Mice via Non-CB1, Non-CB2 Mechanism","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.111.187815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}